Global Alpha-1 Antitrypsin (AAT) Usage in 2024 & Forecast to 2032
An analysis of the GLOBAL alpha-1 antitrypsin (aat) MARKET IN 2024
AND FORECAST TO THE YEAR 2032
Alpha-1 Antitrypsin (AAT) is the third most important plasma derived protein in terms of global sales, after immunoglobulins and albumin. Since its market introduction in the 1980s, it has enjoyed decades of growth, which continues today. Unlike many specialty plasma fractions, there has been no novel or recombinant competition to AAT to date, though there are a number of potential therapies in clinical trials which could potentially alter the market for plasma derived alpha-1 in the coming years.
This new report details current AAT usage around the globe and takes a deep look at the potential upcoming competition and innovation in the Alpha-1 Antitrypsin Deficiency (AATD) market. This includes plasma derived AAT innovations like higher dosing, and briefly, inhaled and subcutaneous offerings. Based on a long-term and extensive understanding of the AAT market, MRB’s forecast model analyzes both key drivers of increased plasma-derived AAT growth and how new competitive products might affect those sales.
This report covers the sales of AAT in all countries in 2024 with significant AAT sales. Assumptions used to forecast AAT unit volume and pricing are based on (1) actual MRB sales data collected in dozens of countries globally, (2) expert opinions on AAT usage today and how it will change in the future, (3) MRB’s analysis of novel competition which will affect plasma-derived and recombinant AAT demand based on analogs and deep market understanding, and (4) AAT pricing dynamics.
For 2025 through 2032, the report forecasts country-level AAT product sales in units, prices and sales in US dollars. There are separate forecasts for plasma derived and recombinant products. Special consideration, detail and explanation was given to the United States as the largest market for AAT globally. Other key markets are also given additional commentary. Competition from alternative therapies and budget constraints in many countries are implicitly covered in this forecast based on MRB’s extensive global understanding of country level dynamics and the plasma industry behavior.
See the complete Table of Contents below for more details about the contents of this report. Email us for pricing of this report by hitting Contact Us
TABLE OF CONTENTS
EXECUTIVE SUMMARY 3
1) OVERVIEW OF ALPHA-1 ANTITRYPSIN (AAT) AND USE 19
1.1) Definition and Role of Alpha-1 Antitrypsin 19
1.2) Alpha 1 Antitrypsin Deficiency (AATD) and Treatment 20
Discovery and Clinical Role of Alpha-1 Antitrypsin 20
Prevalence of Alpha1 Antitrypsin Disease (AATD) 24
Alpha-1 Antitrypsin Patient Organizations and Registries 27
1.3) Current Standard of Care in Alpha 1 Antitrypsin Disease 28
Testing for Alpha-1 Antitrypsin Deficiency (AATD) 32
2) ALPHA-ONE ANTITRYPSIN PRODUCT PIPELINE 34
2.1) AAT Product Currently Available 34
2.2) New products under Development for AATD 36
Alpha-1 Antitrypsin Protein therapies in clinical development 36
Non-Plasma derived AAT product developments 39
Gene Therapy 42
Other developments for AATD in pre-clinical stage: 44
3) FORECAST ASSUMPTIONS 49
4) AAT USAGE & FORECAST IN NORTH AMERICA 56
4.1) 2024 AAT Usage in North America 56
Current AAT Use in the United States 58
Current AAT Use in Canada 60
4.2) Forecast to 2032 in North America 61
United States Forecast Trends 68
Canada Forecast Trends 75
5) AAT USAGE & FORECAST IN EUROPE 78
5.1) 2024 AAT Usage in Europe 78
Current AAT market in high usage European countries 79
Current AAT market in low usage European countries 86
5.2) Forecast to 2032 in Europe 88
Forecast trends in High-Use Countries 101
Forecast trends in Low-Use Countries in Europe 109
Forecast trends in other Countries in Europe 110
6) AAT USAGE & FORECAST IN OTHER REGIONS 114
6.1) Asia & Pacific AAT Usage 114
6.2 Middle East & Africa AAT Usage 120
6.3) Latin America AAT Usage 127
7) WORLDWIDE ALPHA-1 ANTITRYPSIN USAGE AND FORECAST TO 2032 135
7.1) 2024 Worldwide AAT Usage Summary 135
7.2) Worldwide Forecast to 2032 144